- Turkish Journal of Medical Sciences
- Vol: 38 Issue: 5
- Serum Dehydroepiandrosterone Sulfate Usage for Early Detection of Prostate Cancer in Men with Serum ...
Serum Dehydroepiandrosterone Sulfate Usage for Early Detection of Prostate Cancer in Men with Serum Prostate Specific Antigen Level between 2.5 and 4.0 ng/ml: A Pilot Study
Authors : Yılmaz Aslan, Ümit Tekdoğan, Altuğ Tuncel, Metin Burçin Uzun, Erdem Karabulut, Ali Atan
Pages : 399-404
View : 21 | Download : 5
Publication Date : 9999-12-31
Article Type : Makaleler
Abstract :Aims: We prospectively evaluated the diagnostic value of serum prostate specific antigen (PSA)-based diagnostic parameters and serum dehydroepiandrosterone sulfate (DHEAS) level for early detection of prostate cancer in patients with serum PSA level between 2.5 and 4 ng/ml. Materials and Methods: This study included 83 consecutive men with serum PSA levels between 2.5 and 4.0 ng/ml. All patients underwent transrectal ultrasound-guided prostate needle biopsy. Total PSA level, free/total PSA ratio, PSA density of the total volume (PSAD-TV), PSA density of the transition zone (PSAD-TZ), and serum DHEAS values were determined. Results: Seventy-four patients (89.2%) had histopathologically confirmed benign prostatic hyperplasia and the remaining (10.8%) had prostate cancer. DHEAS was a significant predictor of prostate cancer compared to free/total PSA ratio, PSAD-TV and PSAD-TZ (PDHEAS = 0.012, Pfree/total PSA = 0.326, PPSAD-TV = 0.884, PPSAD-TZ = 0.203). If the cut-off point of DHEAS was considered 1,700 ng/ml, sensitivity and specificity of DHEAS were 100% and 59.4%, respectively. This cut-off point might lead to avoiding 40.9% of unnecessary prostate biopsies. Conclusions: Serum DHEAS seems to be a reasonable marker for early detection of prostate cancer and can avoid unnecessary prostate biopsy in patients whose serum PSA level is between 2.5 and 4 ng/ml.Keywords : Prostate cancer, prostate specific antigen, dehydroepiandrosterone sulfate